Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has 6 years of Receivables - Other data on file, last reported at $20.0 million in Q1 2025.

• On a quarterly basis, Receivables - Other rose 885.22% year-over-year to $20.0 million in Q1 2025; TTM through Mar 2025 was $20.0 million, a 885.22% increase from a year earlier, with the FY2024 full-year figure at $947000.0, down 75.08% from the prior year.
• Receivables - Other for Q1 2025 stood at $20.0 million, up from $900000.0 in the prior quarter.
• Over the last five years, Receivables - Other for KYMR reached as high as $20.0 million in Q1 2025 and fell as low as $100000.0 in Q4 2021.
• Historically, Receivables - Other has averaged $3.2 million across 5 years, with a median of $2.0 million in 2024.
• Across the five-year window, Receivables - Other slumped 82.67% in 2021 and soared 2437.0% in 2022, its largest moves.
• Year by year, Receivables - Other stood at $100000.0 in 2021, then surged by 2437.0% to $2.5 million in 2022, then soared by 48.29% to $3.8 million in 2023, then tumbled by 76.08% to $900000.0 in 2024, then surged by 2122.22% to $20.0 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $20.0 million in Q1 2025, $900000.0 in Q4 2024, and $1.3 million in Q3 2024.